Brief: Celldex Therapeutics Presents Positive Data From Barzolvolimab Phase 1b Study In Chronic Inducible Urticaria

Celldex Therapeutics

06/12/2022 11:58

Dec 6 (Reuters) - Celldex Therapeutics Inc  CLDX.O :
    * CELLDEX THERAPEUTICS PRESENTS POSITIVE DATA FROM
BARZOLVOLIMAB
PHASE 1B STUDY IN CHRONIC INDUCIBLE URTICARIA AT GLOBAL
URTICARIA FORUM 2022
    * CELLDEX THERAPEUTICS INC - ANNOUNCED NEW DATA FROM CO'S
OPEN
LABEL PHASE 1B CLINICAL TRIAL OF BARZOLVOLIMAB
    * CELLDEX THERAPEUTICS INC - 100% COMPLETE RESPONSE RATE IN
COLD
URTICARIA AFTER SINGLE DOSE OF BARZOLVOLIMAB AT 1.5 MG/KG
    * CELLDEX THERAPEUTICS INC - PATIENTS TREATED AT 3.0 MG/KG
CONFIRM
BARZOLVOLIMAB-INDUCED RESPONSES, MAST CELL SUPPRESSION ARE
DURABLE, LINKED

Source text for Eikon:  ID:nGNX2qsHrc 
Further company coverage:  CLDX.O 
 ((Reuters.Briefs@thomsonreuters.com;))